Zacks Research Issues Optimistic Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research boosted their Q1 2027 EPS estimates for shares of Prestige Consumer Healthcare in a research report issued on Tuesday, April 22nd. Zacks Research analyst R. Department now forecasts that the company will earn $1.11 per share for the quarter, up from their prior estimate of $1.09. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Royal Bank of Canada raised their target price on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Hold” and an average price target of $93.33.

Prestige Consumer Healthcare Price Performance

PBH opened at $80.52 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04. The stock’s 50 day simple moving average is $83.60 and its 200 day simple moving average is $80.56. The firm has a market cap of $3.99 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 2.69 and a beta of 0.47.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth about $84,932,000. Raymond James Financial Inc. acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $42,593,000. Norges Bank purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,009,000. Bessemer Group Inc. lifted its position in Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after buying an additional 292,144 shares in the last quarter. Finally, Boston Trust Walden Corp boosted its stake in Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after buying an additional 252,089 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.